| Item type |
文献 / Documents(1) |
| 公開日 |
2024-07-18 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
関連識別子 |
https://doi.org/10.1016/j.rmcr.2023.101893 |
|
|
関連名称 |
10.1016/j.rmcr.2023.101893 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
FoundationOne CDx detected an uncovered variant of epidermal growth factor receptor exon 19 deletion by Oncomine Dx target test in a patient with lung adenocarcinoma |
| 著者 |
高橋, 浩樹
荻野, 広和
バンドウ, ヒロキ
三橋, 惇志
塚﨑, 佑貴
矢葺, 洋平
尾崎, 領彦
米田, 浩人
佐藤, 正大
埴淵, 昌毅
西岡, 安彦
|
| 抄録 |
|
|
内容記述 |
A non-smoker woman with advanced lung adenocarcinoma was referred to us. The Oncomine Dx target test (ODxTT), a next-generation sequencing (NGS)-based hot spots panel test, did not detect any driver mutations, so we treated her with chemo-immunotherapy. After second-line chemotherapy, we performed FoundationOne CDx, a NGS-based comprehensive genomic profiling (CGP) test, and identified a rare variant of epidermal growth factor receptor exon 19 deletion that had not been covered by ODxTT. This case highlights the importance of considering the indication of a CGP test for patients who are likely to harbor driver mutations, even when ODxTT fails to detect any. |
| キーワード |
|
|
主題 |
Lung adenocarcinoma |
| キーワード |
|
|
主題 |
Oncomine dx target test |
| キーワード |
|
|
主題 |
Comprehensive genomic profiling |
| キーワード |
|
|
主題 |
FoundationOne CDx |
| キーワード |
|
|
主題 |
Driver mutations |
| キーワード |
|
|
主題 |
Epidermal growth factor receptor |
| 書誌情報 |
en : Respiratory Medicine Case Reports
巻 45,
p. 101893,
発行日 2023-07-07
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
22130071 |
| 出版者 |
|
|
出版者 |
Elsevier |
| 権利情報 |
|
|
権利情報 |
© 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| EID |
|
|
識別子 |
405852 |
| 言語 |
|
|
言語 |
eng |
rmcr_45_101893.pdf (4.27 MB)
.png)
